** Shares of biopharma firm Travere Therapeutics TVTX.O rise 3.5% to $20.42
** TVTX says it submitted a marketing application to the U.S. FDA for co's drug, Filspari, for treatment of a rare kidney scarring disease called focal segmental glomerulosclerosis
** Co expects to receive regulatory decision in Q2
** Filspari is currently approved to slow decline in kidney function in adults with immunoglobulin A nephropathy, a leading cause of kidney failure
** Up to last close, TVTX has more than doubled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。